ABSTRACT
Interindividual variation in the activities of drug-metabolising enzymes is one of the principal determinants of variability in the outcome of drug therapy, adverse drug reactions and drug interactions. Furthermore, it complicates extrapolations during drug development, dose titration during clinical trials and is often behind morbidity and mortality in drug treatment.
